Patents Examined by Jason Nolan
  • Ophthalmic compositions for treating ocular hypertension
    Patent number: 7494983
    Abstract: This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: February 24, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Meng Hsin Chen, James B. Doherty, Luping Liu, Swaminathan Natarajan, Robert M. Tynebor
  • Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
    Patent number: 7491725
    Abstract: The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R2, R3, R4, and R5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: February 17, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jean Lajeunesse, John D. DiMarco, Michael Galella, Ramakrishnan Chidambaram
  • Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
    Patent number: 7485754
    Abstract: Provided is an efficient method for the preparation of 3-aryloxy-3-arylpropylamines, their optical stereoisomers, and pharmaceutically acceptable salts thereof. The process allows for the isolation of 3-aryloxy-3-arylpropylamines in high yield and purity. The present invention further relates to a process for producing fluoxetine, tomoxetine, norfluoxetine, duloxetine, nisoxetine, and their optically enriched (R)- and (S)-enantiomers.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: February 3, 2009
    Assignee: Apotex Pharmachem Inc.
    Inventors: Zhi-Xian Wang, Mohammed Abdul Raheem, Gamini Weeratunga, Bhaskar Reddy Guntoori
  • Indolyl derivatives as liver-X-receptor (LXR) modulators
    Patent number: 7485652
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: February 3, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Henrietta Dehmlow, Bernd Kuhn, Narendra Panday, Hasane Ratni, Tanja Schulz-Gasch, Matthew Blake Wright
  • Compounds and compositions as cathepsin inhibitors
    Patent number: 7482448
    Abstract: Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: January 27, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Sukanthini Thurairatnam, David John Aldous, Vincent Leroy, Andreas Paul Timm
  • Modulators of LXR
    Patent number: 7482366
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: July 24, 2004
    Date of Patent: January 27, 2009
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Christopher D Bayne, Alan T Johnson, Shao-Po Lu, Raju Mohan, Michael C Nyman, Edwin J Schweiger, William C Stevens, Jr., Haixia Wang, Yinong Xie
  • Pyrrolidine-2-ones as Factor Xa inhibitors
    Patent number: 7482374
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Grant
    Filed: July 17, 2004
    Date of Patent: January 27, 2009
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Henry Anderson Kelly, Nigel Stephen Watson, Robert John Young
  • Heterocyclic arylsulfonamidobenzylic compounds
    Patent number: 7473703
    Abstract: Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: January 6, 2009
    Assignee: Amgen Inc.
    Inventors: Xian Yun Jiao, Frank Kayser, David J. Kopecky, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
  • Pyrazole-amine compounds for the treatment of neurodegenerative disorders
    Patent number: 7468386
    Abstract: The present invention relates to compounds of the Formula wherein R1, R3, R4, R5, R6, R7 and R8 are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: December 23, 2008
    Assignee: Pfizer Inc.
    Inventors: Yuhpyng L. Chen, Lei Zhang